This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

AVROBIO Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

AVROBIO yıllık ortalama 14.5% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 19% annual.

Anahtar bilgiler

14.5%

Kazanç büyüme oranı

24.6%

EPS büyüme oranı

Biotechs Sektör Büyümesi	17.0%
Gelir büyüme oranı	n/a
Özkaynak getirisi	34.1%
Net Marj	n/a
Son Kazanç Güncellemesi	31 Mar 2024

Yakın geçmiş performans güncellemeleri

Güncelleme yok

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

Gelir ve Gider Dağılımı

AVROBIO nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:AVRO Gelir, gider ve kazançlar (USD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 24	30	22	27
31 Dec 23	12	23	44
30 Sep 23	-4	26	61
30 Jun 23	-5	27	63
31 Mar 23	-101	31	70
31 Dec 22	-106	33	72
30 Sep 22	-109	35	73
30 Jun 22	-119	38	80
31 Mar 22	-122	38	84
31 Dec 21	-119	36	83
30 Sep 21	-119	35	84
30 Jun 21	-123	34	89
31 Mar 21	-121	33	87
31 Dec 20	-120	33	87
30 Sep 20	-114	31	85
30 Jun 20	-95	28	69
31 Mar 20	-82	24	61
31 Dec 19	-73	21	55
30 Sep 19	-66	18	51
30 Jun 19	-61	16	47
31 Mar 19	-55	14	42
31 Dec 18	-49	11	35
30 Sep 18	-40	8	29
30 Jun 18	-35	6	25
31 Mar 18	-27	5	19
31 Dec 17	-19	3	15

Kaliteli Kazançlar: AVRO büyük bir tek seferlik kazanç ile $75.9M, 31st March, 2024 tarihine ait son 12 aylık mali sonuçları etkiliyor.

Büyüyen Kar Marjı: AVRO geçmişte karlı hale geldi.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AVRO son 5 yılda karlı hale geldi ve kazançlarını yıllık 14.5% oranında artırdı.

Büyüme Hızlandırma: AVRO son bir yılda karlı hale geldi, bu da kazanç büyüme oranının 5 yıllık ortalamayla karşılaştırılmasını zorlaştırıyor.

Kazançlar vs. Sektör: AVRO son bir yılda karlı hale geldi ve bu durum, geçmiş yıl kazanç büyümesinin Biotechs sektörüyle ( -15% ) karşılaştırılmasını zorlaştırıyor.

Özkaynak Getirisi

Yüksek ROE: AVRO 'nin Özsermaye Getirisi ( 34.1% ) yüksek olarak değerlendiriliyor.

This company is no longer active

AVROBIO Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline

AVROBIO EPS misses by $0.19

Price target raised to US$38.50

Avrobio, Inc. Enters into Agreement with University of Manchester, England

Avrobio, Inc. Receives Orphan Drug Designation from the European Medicines Agency for Avr-Rd-02, an Investigational Gene Therapy for Gaucher Disease

New 90-day low: US$15.00

New 90-day low - US$15.85

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin